Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Hoth Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Hoth Therapeutics, Inc.

HOTH

Hoth Therapeutics, Inc.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for unmet medical needs, including treatments for cancer-related skin toxicities, mast cell cancers, neuroinflammatory diseases, eczema, asthma, allergies, and obesity. It leverages proprietary formulations, licensing agreements, and innovative drug platforms to address significant health conditions, relying on third-party manufacturing and regulatory approval processes to bring its products to market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Hoth Therapeutics, Inc.

1
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports Q1 2026 Financial Results with $2.69M Net Loss

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports $12.5 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports $4.1 Million Net Loss for Third Quarter 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports $2.2 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports $3.5 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports $8.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Hoth Therapeutics, Inc. Hoth Therapeutics Reports Third Quarter and Nine Months Financial Results, Reduces Losses Amid Focus on Development Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments